BRISBANE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced it will present data on validation of AlloSure at the 2016 Annual Meeting of Association for Molecular Pathology (AMP) in Charlotte, North Carolina.
AlloSure is a clinical-grade proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in solid organ transplant recipients. The results that will be presented expand on the validation of AlloSure that was recently published by The Journal of Molecular Diagnostics and were highlighted in an associated journal press release.
Three abstracts are to be presented at AMP, each providing further validation of the AlloSure assay.
Following is a summary of the abstracts that will be presented at AMP 2016:
Donor-Derived Cell-Free DNA, a Non-invasive Marker for Transplanted Organ Injury: Accurate and Precise Measurement without Prior Genotyping Regardless of Donor-Recipient Familial Relationship
(TT50) Date/Time: Friday, November 11, 2:30pm – 3:30pm
Beyond Analytical Validity: Each step in the testing process is robustly demonstrated as accurate from specimen acquisition to final result reporting
(TT44) Date/Time: Friday, November 11, 2:30pm – 3:30pm
Donor-Derived Cell-Free DNA Is Successfully Quantified in HLA-matched Kidney Transplantation
(G33) Date/Time: Saturday, November 12, 9:45am – 10:45am
“We are thrilled that the scientific community is embracing our integration of NGS recommended guidelines from AMP, CAP, NYDOH and other professional organizations for analytical validation of AlloSure. The data presented at the AMP annual meeting provide evidence for reliable testing of dd-cfDNA in related donors and HLA-matched patients, increasing the range of patients for which physicians can confidently test.” says John J. Sninsky, Chief Scientific Officer, CareDx, Inc.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements including, but not limited to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including the continued successful development and planned commercialization of AlloSure, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 filed by us with the SEC on August 22, 2016. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Investor Contact Jamar Ismail, Westwicke Partners T: +1 415-513-1282 email@example.com